- Home
- Healthcare professionals
- ACE Technology Guidances
- Drug Guidance
- Intravenous infliximab biosimilars for treating inflammatory conditions
Drug guidance
Intravenous infliximab biosimilars for treating inflammatory conditions
Condition
Musculoskeletal
Gastrointestinal tract
Skin
13 September 2024
Published on 18 Jan 2021
Last Updated on 13 Sep 2024
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has recommended to:
Reclassify infliximab biosimilar (Remsima) 100 mg vial from the Medication Assistance Fund (MAF) to the MOH Standard Drug List (SDL); and
List infliximab biosimilar (Ixifi) 100 mg vial on the SDL
in view of favourable cost effectiveness compared to other anti-tumour necrosis factor alfa (anti-TNFα) biologics at the prices proposed by the manufacturers.
Subsidy status
SDL subsidy will apply for all registered indications of infliximab biosimilar 100 mg vial (Remsima and Ixifi) in Singapore:
Adults with moderately to severely active rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, ulcerative colitis or Crohn’s disease;
Children aged 6 years or older with severe active Crohn’s disease; and
Children aged 6 years or older with moderately to severely active ulcerative colitis.
SDL subsidy does not apply to proprietary infliximab 100 mg vial (Remicade) or other brands of infliximab biosimilars.
Previous versions of the guidance may be found here.